HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Petr Chytil Selected Research

pirarubicin

1/2020Highly effective anti-tumor nanomedicines based on HPMA copolymer conjugates with pirarubicin prepared by controlled RAFT polymerization.
1/2019Superior Penetration and Cytotoxicity of HPMA Copolymer Conjugates of Pirarubicin in Tumor Cell Spheroid.
1/2018HPMA copolymer conjugate with pirarubicin: In vitro and ex vivo stability and drug release study.
2/2016HPMA Copolymer-Conjugated Pirarubicin in Multimodal Treatment of a Patient with Stage IV Prostate Cancer and Extensive Lung and Bone Metastases.
2/2015Comparison between linear and star-like HPMA conjugated pirarubicin (THP) in pharmacokinetics and antitumor activity in tumor bearing mice.
1/2014Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Petr Chytil Research Topics

Disease

40Neoplasms (Cancer)
10/2022 - 12/2005
6T-Cell Lymphoma (Lymphoma, T Cell)
11/2017 - 09/2006
2Prostatic Neoplasms (Prostate Cancer)
10/2020 - 02/2016
2Neoplasm Metastasis (Metastasis)
10/2020 - 02/2016
1Bacterial Infections (Bacterial Infection)
02/2021
1Inflammation (Inflammations)
02/2021
1Melanoma (Melanoma, Malignant)
10/2020
1Cardiotoxicity
11/2018
1Lymphoma (Lymphomas)
11/2018
1Mitochondrial Diseases (Mitochondrial Disease)
10/2018
1Neuroblastoma
11/2017
1Carcinoma (Carcinomatosis)
11/2016

Drug/Important Bio-Agent (IBA)

26hydroxypropyl methacrylateIBA
02/2021 - 12/2005
23Pharmaceutical PreparationsIBA
10/2020 - 12/2005
21PolymersIBA
01/2021 - 12/2008
16N-(2-hydroxypropyl)methacrylamideIBA
01/2021 - 12/2005
14Doxorubicin (Adriamycin)FDA LinkGeneric
11/2018 - 12/2005
6pirarubicinIBA
01/2020 - 01/2014
6Drug CarriersIBA
12/2018 - 12/2013
5Biological ProductsIBA
01/2021 - 11/2016
4Cytostatic AgentsIBA
01/2021 - 09/2006
4BuffersIBA
01/2021 - 04/2011
4methacrylamideIBA
01/2020 - 11/2017
4CholesterolIBA
12/2018 - 08/2012
4HydrazonesIBA
11/2018 - 01/2014
3Proteins (Proteins, Gene)FDA Link
01/2021 - 12/2018
3ProdrugsIBA
11/2018 - 11/2017
2Galectin 3 (LGALS3)IBA
10/2022 - 10/2020
2SolutionsIBA
10/2020 - 01/2018
2Fluorescent Dyes (Fluorescent Probes)IBA
11/2018 - 01/2018
2Ritonavir (Norvir)FDA Link
10/2018 - 11/2017
2Member 1 Subfamily B ATP Binding Cassette TransporterIBA
10/2018 - 11/2017
2Therapeutic UsesIBA
01/2018 - 02/2015
2AcidsIBA
02/2015 - 01/2014
1N- acetylgalactosaminyl- 1- 4- N- acetylglucosamineIBA
10/2020
1Free RadicalsIBA
01/2020
1Antineoplastic Agents (Antineoplastics)IBA
01/2019
1AnthracyclinesIBA
11/2018
1Phosphates (Orthophosphate)IBA
10/2018
1CaveolinsIBA
10/2018
1Adenosine Triphosphate (ATP)IBA
10/2018
1Arginine (L-Arginine)FDA Link
01/2018
1MicellesIBA
01/2018
1Docetaxel (Taxotere)FDA Link
01/2017
1Betulinic AcidIBA
11/2016
1Protons (Proton)IBA
02/2016
1DuxonIBA
02/2015
1HydrazinesIBA
01/2014
1butyleneIBA
01/2013
1bionoleIBA
01/2013
1OligopeptidesIBA
09/2011
1SuspensionsIBA
09/2011
1EnzymesIBA
04/2011
1Cathepsin BIBA
04/2011

Therapy/Procedure

12Therapeutics
10/2022 - 12/2005
3Drug Therapy (Chemotherapy)
11/2018 - 12/2005
1Precision Medicine
08/2017
1Radiotherapy
02/2016
1Combined Modality Therapy
02/2016